Clinical evaluation reveals that peripheral exhaled nitric oxide marks type 2 inflammation in COPD, highlighting its utility in guiding corticosteroid therapy.
FeNO₂₀₀ is a straightforward and feasible method to evaluate the peripheral NO concentration in COPD. FeNO200 can be a type 2 inflammation biomarker and a useful tool for predicting corticosteroid therapy in COPD.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: